Circulating levels of myocardial proteins predict future deterioration of congestive heart failure

Journal of Cardiac Failure

Volumn 11, Issue 7, 2005, Pages 504-509

  Sugiura, Tomonori ^a   Takase, Hiroyuki ^a   Toriyama, Takayuki ^a   Goto, Takatoshi ^b   Ueda, Ryuzo ^b   Dohi, Yasuaki ^b  

^a Enshu General Hospital   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Creatine kinase isoenzyme MB; Heart fatty acid binding protein; Myosin light chain I; Troponin T

Indexed keywords

CREATINE KINASE MB; FATTY ACID BINDING PROTEIN; MYOSIN LIGHT CHAIN; TROPONIN T;

AGED; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

AGE FACTORS; AGED; BIOLOGICAL MARKERS; CARDIOMYOPATHY, DILATED; CREATINE KINASE, MB FORM; FATTY ACID-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MULTIVARIATE ANALYSIS; MYOCARDIUM; MYOSIN LIGHT CHAINS; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; ROC CURVE; TROPONIN T;

EID: 25844486969     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2005.04.025     Document Type: Article

References (30)

1. J.G. Cleland, K. Swedberg, and P.A. Poole-Wilson Successes and failures of current treatment of heart failure Lancet 352 Suppl 1 1998 SI19 SI28
2. K.K. Ho, K.M. Anderson, W.B. Kannel, W. Grossman, and D. Levy Survival after the onset of congestive heart failure in Framingham Heart Study subjects Circulation 88 1993 107 115
3. G.S. Francis, J.N. Cohn, G. Johnson, T.S. Rector, S. Goldman, and A. Simon Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group Circulation 87 Suppl 1993 VI40 VI48
4. R.W. Schrier, and W.T. Abraham Hormones and hemodynamics in heart failure N Engl J Med 341 1999 577 585
5. R. Willenbrock, S. Philipp, V. Mitrovic, and R. Dietz Neurohumoral blockade in CHF management J Renin Angiotensin Aldosterone Syst 1 Suppl 1 2000 24 30
6. J.N. Cohn, T.B. Levine, G.S. Francis, and S. Goldsmith Neurohumoral control mechanisms in congestive heart failure Am Heart J 102 1981 509 514
7. V.J. Dzau Contributions of neuroendocrine and local autocrine-paracrine mechanisms to the pathophysiology and pharmacology of congestive heart failure Am J Cardiol 62 1988 76E 81E
8. A.J. Riegger Hormones in heart failure - regulation and counterregulation Eur Heart J 12 Suppl D 1991 190 192
9. W.S. Colucci Molecular and cellular mechanisms of myocardial failure Am J Cardiol 80 1997 15L 25L
10. J.N. Cohn Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition Circulation 91 1995 2504 2507
11. J. Ishii, M. Nomura, Y. Nakamura, H. Naruse, Y. Mori, and T. Ishikawa Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure Am J Cardiol 89 2002 691 695
12. M.S. Hansen, E.B. Stanton, Y. Gawad, M. Packer, B. Pitt, and K. Swedberg Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan Am J Cardiol 90 2002 969 973
13. C.H. Del Carlo, A.C. Pereira-Barretto, C. Cassaro-Strunz, R. Latorre Mdo, and J.A. Ramires Serial measure of cardiac troponin T levels for prediction of clinical events in decompensated heart failure J Card Fail 10 2004 43 48
14. K. Setsuta, Y. Seino, T. Ogawa, M. Arao, Y. Miyatake, and T. Takano Use of cytosolic and myofibril markers in the detection of ongoing myocardial damage in patients with chronic heart failure Am J Med 113 2002 717 722
15. T. Goto, H. Takase, T. Toriyama, T. Sugiura, K. Sato, and R. Ueda Circulating levels of cardiac proteins indicate severity of congestive heart failure Heart 89 2003 1303 1307
16. M. Mukoyama, K. Nakao, K. Hosoda, S. Suga, Y. Saito, and Y. Ogawa Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide J Clin Invest 87 1991 1402 1412
17. T.A. McDonagh, A.D. Cunningham, C.E. Morrison, J.J. McMurray, I. Ford, and J.J. Morton Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population Heart 86 2001 21 26
18. T. Tsutamoto, A. Wada, K. Maeda, T. Hisanaga, N. Mabuchi, and M. Hayashi Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1 Eur Heart J 20 1999 1799 1807
19. J. Koglin, S. Pehlivanli, M. Schwaiblmair, M. Vogeser, P. Cremer, and W. vonScheidt Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure J Am Coll Cardiol 38 2001 1934 1941
20. C.M. Wei, D.M. Heublein, M.A. Perrella, A. Lerman, R.J. Rodeheffer, and C.G. McGregor Natriuretic peptide system in human heart failure Circulation 88 1993 1004 1009
21. J. Schaper, R. Froede, S. Hein, A. Buck, H. Hashizume, and B. Speiser Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy Circulation 83 1991 504 514
22. C.A. Beltrami, N. Finato, M. Rocco, G.A. Feruglio, C. Puricelli, and E. Cigola Structural basis of end-stage failure in ischemic cardiomyopathy in humans Circulation 89 1994 151 163
23. C.H. Davies, S.E. Harding, and P.A. Poole-Wilson Cellular mechanisms of contractile dysfunction in human heart failure Eur Heart J 17 1996 189 198
24. M.A. Gaballa, and S. Goldman Ventricular remodeling in heart failure J Card Fail 8 Suppl 2002 S476 S485
25. L. Jiang, Y. Huang, S. Hunyor, and C.G. dos Remedios Cardiomyocyte apoptosis is associated with increased wall stress in chronic failing left ventricle Eur Heart J 24 2003 742 751
26. N. Haider, N. Narula, and J. Narula Apoptosis in heart failure represents programmed cell survival, not death, of cardiomyocytes and likelihood of reverse remodeling J Card Fail 8 6 Suppl 2002 S512 S517
27. M.M. Givertz, and W.S. Colucci New targets for heart-failure therapy: endothelin, inflammatory cytokines, and oxidative stress Lancet 352 Suppl I 1998 SI34 SI38
28. M. Cristina Polidori, D. Pratico, K. Savino, J. Rokach, W. Stahl, and P. Mecocci Increased F2 isoprostane plasma levels in patients with congestive heart failure are correlated with antioxidant status and disease severity J Card Fail 10 2004 334 338
29. M. Nonaka-Sarukawa, K. Yamamoto, H. Aoki, H. Takano, T. Katsuki, and U. Ikeda Increased urinary 15-F2t-isoprostane concentrations in patients with non-ischaemic congestive heart failure: a marker of oxidative stress Heart 89 2003 871 874
30. G.S. Francis, and W.H. Tang Pathophysiology of congestive heart failure Rev Cardiovasc Med 4 Suppl 2 2003 S14 S20